Drugs / SB-728mR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02225665 | Aug 2014 → Jun 2018 | HIV infectious disease | Sangamo Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-728mR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02225665 ↗ |
| Action | Inhibit | “Disruption of CCR5 by zinc finger nuclease (SB-728mR), blocks HIV entry into the T-cells” NCT02225665 ↗ |
| Modality | Cell therapy | “autologous T-cells genetically modified at the CCR5 gene by Zinc Finger Nucleases” NCT02225665 ↗ |
| Target | CCR5 | “Disruption of CCR5 by zinc finger nuclease (SB-728mR), blocks HIV entry into the T-cells” NCT02225665 ↗ |